AnaptysBio to abandon eczema drug development after mid-stage trial failure
AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed to meet the goals of a ...
AnaptysBio’s atopic dermatitis trial of BTLA agonist misses endpoints
AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...
AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data
AnaptysBio, Inc. (NASDAQ:ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary ...
Fintel on MSN10h
HC Wainwright & Co. Downgrades AnaptysBio (ANAB)
Fintel reports that on December 11, 2024, HC Wainwright & Co. downgraded their outlook for AnaptysBio (NasdaqGS:ANAB) from ...
FierceBiotech19h
AnaptysBio scraps atopic dermatitis asset after antibody fails to meet all endpoints in ph. 2
AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...
The Pharma Letter17h
AnaptysBio drops development of ANB032 following trial miss
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary ...
AnaptysBio announces Phase 2b trial of ANB032 did not meet primary endpoint
AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses ...
AnaptysBio (ANAB) Receives a Buy from TD Cowen
TD Cowen analyst Joseph Thome maintained a Buy rating on AnaptysBio (ANAB – Research Report) today. The company’s shares opened today at ...
AnaptysBio to Drop Eczema Drug Candidate After Trials Miss Endpoints; Shares Fall
The clinical-stage biotechnology company said its investigational drug ANB032 didn't meet either primary or secondary endpoints in its 201-patient Arise-AD trial as a therapy for atopic dermatitis, ...
Anaptys scraps development of ANB032, stock plunges 33%
Anaptys Bio (NASDAQ:ANAB) stock plunged 33% Wednesday after the company said it was scrapping further development of its drug ...
Investors Slaughter Q32 Bio On A 'Messy' Update In Eczema, Alopecia Treatment
Q32 Bio delivered a "messy" update for its eczema and alopecia treatment, leading the biotech stock to collapse to a record ...
The New York Times13h
New York Times - Top Stories
Christopher Wray Will Step Down as F.B.I. Director President-elect Trump had already signaled his intention to replace Mr. Wray with a longtime loyalist, Kash Patel. U.S. Colleges Warn Foreign ...